Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab - Wikidata - awgldk - TriplyDB

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

http://www.wikidata.org/entity/Q24598109

about

Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms Treatment of neuromyelitis optica: state-of-the-art and emerging therapies Optic neuritis in neuromyelitis optica.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Aquaporins: important but elusive drug targets.Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks.IL-6 in inflammation, immunity, and disease The treatment of neuromyelitis optica.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination.Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder.Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.Immunotherapy targeting cytokines in neuropathic pain.The fundamental unit of pain is the cell.Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.Monoclonal antibodies in treatment of multiple sclerosis.Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications.B cells in MS and NMO: pathogenesis and therapy.Th17 cells in neuromyelitis optica spectrum disorder: a review.Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.What's new in neuromyelitis optica? A short review for the clinical neurologist.Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder.

P2860

Q21146701-C7AF3B2C-0486-4C86-8F63-CC56790A932A Q27006941-1AF65861-D058-4A99-BA56-1C757DF51D3B Q28245749-3F139532-4381-47C2-91DB-5B561749F7F5 Q30610471-89D36975-3E94-448E-961B-6F1BC5440D46 Q30676331-2A644FF8-0D66-4C04-B408-C3822D23B6FF Q30785267-AE93D9FE-EDDB-4D1E-B409-C12F2B0F2EC8 Q33792739-9E0B9ADD-BA96-4591-A790-9140DCD8A040 Q34235490-F003C800-A78F-46E2-BE1E-504427762D10 Q34248105-17979F86-41BB-406B-8899-C7FE40B9F1BE Q34399291-C9BC74AC-C3B2-4DDA-A933-6562F5454DB3 Q35052199-D21618E8-9FA7-48E2-8E07-086911AE5BB0 Q35067939-EA69AA02-01FF-49F4-8020-00BE366CFFD9 Q35937581-47E4F971-DCA4-42A7-AE35-3BB1C41B1D15 Q36118869-BA65BAF1-947B-4F0C-8493-369C83CF6636 Q36484394-D4E77E13-F418-4F54-A070-88D35EF15509 Q36547012-FEC9892A-2AF2-4DCA-A161-F07623070355 Q36761844-833D08A8-A7A2-4EC1-8E52-01D7B93D7C56 Q37334025-CA8AE2E8-91BD-49BB-8A85-401E6478508F Q37381403-B182ABB4-01F4-456C-8B90-BA8AF4D2B4E0 Q37684228-7714BFAB-B5E3-4A6F-A789-8B8AFFBAAAE3 Q37725870-46081CE4-4861-441A-B0B1-B55FB237D379 Q38133865-23360ABD-9E45-4675-8506-309E2CD0D1F4 Q38171871-C1892325-E53E-49C8-A6A3-337E2520EDE1 Q38212081-1FC5B301-085A-4692-964C-D52ECBD35DBE Q38765404-5802C0B1-8546-40A0-8B9E-F55787BB6EB6 Q38816869-E77C5E02-182D-4A2A-A061-040403FF3535 Q39176987-F3BF4DBA-951F-42BF-ADF2-2A4149927029 Q41962690-783B911C-CA5A-4179-B48C-58D8A269ADD5

P2860

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

http://www.wikidata.org/entity/Q24598109

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Clinical improvement in a pati ...... onoclonal antibody tocilizumab

@ast

Clinical improvement in a pati ...... onoclonal antibody tocilizumab

@en

Clinical improvement in a pati ...... onoclonal antibody tocilizumab

@nl

type

label

Clinical improvement in a pati ...... onoclonal antibody tocilizumab

@ast

Clinical improvement in a pati ...... onoclonal antibody tocilizumab

@en

Clinical improvement in a pati ...... onoclonal antibody tocilizumab

@nl

prefLabel

Clinical improvement in a pati ...... onoclonal antibody tocilizumab

@ast

Clinical improvement in a pati ...... onoclonal antibody tocilizumab

@en

Clinical improvement in a pati ...... onoclonal antibody tocilizumab

@nl

P1433

Q24598109-13FF1618-DC6E-4A5A-A426-2342F9E23E17

P1476

Q24598109-CD6BEFF8-DDBA-45AC-BA18-D0847EBFDCE7

P2093

Q24598109-329249F9-507D-4434-9D14-3C7709B59304

Q24598109-701F4499-4240-4CD5-A6EE-1C8C4570C385

Q24598109-794EDEAA-AF1F-4383-AD9E-5E55919D0E1D

Q24598109-8022B382-50C6-40CA-913D-266B14466EB0

Q24598109-D708CFB3-8A59-409A-87EA-FDDA10FBBAA2

Q24598109-DEA01CF8-B434-40FC-B31A-51BCD42A4683

P2860

Q24598109-0E42003B-914C-4D20-B635-B092B0F600A3

Q24598109-107914A7-794F-47E5-B886-0A8EA2395CAF

Q24598109-181DB849-F59F-475E-812C-68DC0272BF57

Q24598109-1B031E72-6DCC-418E-810B-A97E6914E4E0

Q24598109-1F71EBC8-7638-4CEF-82F5-499EDF6DCDA1

Q24598109-69FCA03A-F243-4165-9A85-965071E17168

Q24598109-8183772A-1042-4D38-B811-7384165F361B

Q24598109-84CFE317-47F1-490D-8572-E72675F2A167

Q24598109-A37C52A6-C96D-4C05-88B6-DC98C4644D5B

Q24598109-B3EC296E-4F7A-4CD3-8143-99B6AF4B52D0

P2888

Q24598109-D453C542-C455-436D-B9F6-A17C4FACF6F0

P304

Q24598109-E0FF8C44-95D7-421A-ADC8-B6E87EC1DCBB

P31

Q24598109-8BA9A3F0-6A2F-4F4E-9162-26146497B57F

P356

Q24598109-478D2060-EA87-4C8B-B26A-3645AE773664

P407

Q24598109-931EFEE0-FD7D-487C-8350-472CF7AC8F61

P433

Q24598109-79F77C14-AF74-42F2-9A9E-AFF93A3251F6

P478

Q24598109-2D060A42-B5D1-4CC1-A7B1-DE9AF14A0FBA

P577

Q24598109-1E8DD6CE-1BD5-4426-92ED-F8E0AB94F9A8

P5875

Q24598109-B0A4F01F-AA30-4F3C-AC60-F035A72225F7

P6179

Q24598109-34F4ED1C-245A-4F44-9BE2-2B09F16E7A5E

P698

Q24598109-A9B4D204-8890-4381-80CC-2074921788F8

P921

Q24598109-63E4EAD4-1342-4AC7-93D0-C2C996A9E959

Q24598109-E5EAED5A-6455-484B-8BE2-B88D87C139A6

P932

Q24598109-34D40729-003A-4046-AE1F-01DBE39AE5E2

P356

S10165-012-0715-9

P1433

Modern Rheumatology

P1476

Clinical improvement in a pati ...... onoclonal antibody tocilizumab

@en

P2093

Manabu Araki

http://www.w3.org/2001/XMLSchema#string

Masakazu Nakamura

http://www.w3.org/2001/XMLSchema#string

Sachiko Miyake

http://www.w3.org/2001/XMLSchema#string

Takako Matsuoka

http://www.w3.org/2001/XMLSchema#string

Takashi Yamamura

http://www.w3.org/2001/XMLSchema#string

Toshimasa Aranami

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Treatment of neuromyelitis optica: current debate.

Revised diagnostic criteria for neuromyelitis optica.

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum.

Therapeutic targeting of the interleukin-6 receptor.

P2888

s10165-012-0715-9

P304

827-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10165-012-0715-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229065155

http://www.w3.org/2001/XMLSchema#string

P6179

1044547693

http://www.w3.org/2001/XMLSchema#string

P698

22782533

http://www.w3.org/2001/XMLSchema#string

P921

P932

3713263

http://www.w3.org/2001/XMLSchema#string